Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia

BACKGROUND: Although first- and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR T790M mutation. The third-generation EGFR-TKI has demonstrated efficacy in patients with progressive disease harboring the T7...

Descripción completa

Detalles Bibliográficos
Autores principales: How, Soon Hin, Liam, Chong Kin, Zainal Abidin, Muhammad Adil, Hasbullah, Harissa H, Tho, Lye Mun, Ho, Gwo Fuang, Muhamad Nor, Ibtisam, Pang, Yong Kek, Ho, Kean Fatt, Thiagarajan, Muthukkumaran, Ariffin, Roziana, Samsudin, Azlina, Omar, Azza, Tan, Sin Nee, Ong, Choo Khoon, Soon, Sing Yang, Poh, Mau Ern
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208817/
https://www.ncbi.nlm.nih.gov/pubmed/35733510
http://dx.doi.org/10.2147/CMAR.S364713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208817/
https://www.ncbi.nlm.nih.gov/pubmed/35733510
http://dx.doi.org/10.2147/CMAR.S364713

Ejemplares similares